Sarcopenia and lean-mass preservation during weight reduction — compounds assessed
The 6 compounds the Institute assesses in sarcopenia and lean-mass preservation during weight reduction.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Approximately 39 % of total mass lost was lean mass in the DXA substudy — The proportion is broadly consistent with dietary weight loss but the substudy is small and single-trial.
Low -
Approximately 25 % of total mass lost was lean mass in the body-composition substudy — Lower lean-mass fraction than reported for dietary weight loss in the same programme, but the substudy is small.
Low -
Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex0 contributing trialsfull monograph
No randomised human evidence identified — Body-composition claims rest on mechanistic reasoning, not on trial evidence.
Very low -
Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide)0 contributing trialsfull monograph
No randomised human evidence identified for a body-composition outcome — Approval for a diagnostic indication is not evidence of therapeutic benefit, and the Institute states this explicitly wherever a diagnostic approval exists.
Very low -
No randomised human evidence identified for this analogue — Native recombinant IGF-1 has an approved indication in severe primary IGF-1 deficiency; that evidence does not transfer to a binding-protein-evading analogue.
Very low -
Growth-hormone secretagogue, selective ghrelin receptor agonist (pentapeptide)0 contributing trialsfull monograph
No randomised human evidence identified — Body-composition claims are not supported by trial evidence.
Very low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.